Patents Examined by Paul J Holland
  • Patent number: 11725198
    Abstract: Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: August 15, 2023
    Assignee: CODEXIS, INC.
    Inventors: David C. Schriemer, Petr Man, Hynek Mrazek, Martial Rey
  • Patent number: 11718840
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 8, 2023
    Assignee: NOVOZYMES A/S
    Inventors: Svend Kaasgaard, Signe Eskildsen Larsen, Jens Oebro, Lars Beier, Connie Pontoppidan, Iben Damager, Carsten Andersen, Allan Svendsen
  • Patent number: 11713471
    Abstract: Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: August 1, 2023
    Assignee: METAGENOMI, INC.
    Inventors: Brian Thomas, Christopher Brown, Audra Devoto, Cristina Butterfield, Lisa Alexander, Daniela S. A. Goltsman, Justine Albers, Alan Brooks, Greg Cost, Morayma Temoche-Diaz, Cindy Castelle, Rebecca Lamothe
  • Patent number: 11702475
    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: July 18, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Shalom Goldberg, Steven Jacobs, Tricia Lin, Karyn O'Neil
  • Patent number: 11702651
    Abstract: The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins further comprise a nuclear localization sequence (NLS), and/or an inhibitor of base repair, such as, a nuclease dead inosine specific nuclease (dISN).
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: July 18, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Nicole Gaudelli
  • Patent number: 11697810
    Abstract: The present disclosure relates to an adenylosuccinate synthetase variant, a microorganism containing the same, and a method for preparing purine nucleotides using the microorganism.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: July 11, 2023
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Min Ji Baek, Ji Hye Lee, So-Jung Park, Jee Yeon Bae
  • Patent number: 11691984
    Abstract: Disclosed herein are methods and compounds for inducing DDB1- and CUL4-associated factor 16 (DCAF16)-mediated protein degradation in mammalian cells. In some embodiments, also disclosed herein are methods of modulating the substrate selectivity of a DCAF16-CUL4-RBX1-DDB1 complex (CRL4) for modulating protein degradation.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 4, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Benjamin Cravatt, Vincent Crowley, Xiaoyu Zhang
  • Patent number: 11685911
    Abstract: Novel lysozyme enzymes from the genus of Rasamsonia.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: June 27, 2023
    Assignee: MONAGHAN MUSHROOM S GROUP
    Inventors: Alison Marie Winger, Ciaran Forde, Anne McMeel, Andrew Dowd, Gabriele Gucciardo
  • Patent number: 11674158
    Abstract: Disclosed herein are homology-independent targeted integration methods of integrating an exogenous DNA sequence into a genome of a non-dividing cell and compositions for such methods. Methods herein comprise contacting the non-dividing cell with a composition comprising a targeting construct comprising the exogenous DNA sequence and a targeting sequence, a complementary strand oligonucleotide homologous to the targeting sequence, and a nuclease, thereby altering the genome of the non-dividing cell.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: June 13, 2023
    Assignee: Salk Institute for Biological Studies
    Inventors: Juan Carlos Izpisua Belmonte, Keiichiro Suzuki, Reyna Hernandez-Benitez, Jun Wu, Yuji Tsunekawa
  • Patent number: 11667887
    Abstract: The present invention relates to a method of producing a recombinant protein in a host cell comprising adding Polyethyleneimine (PEI) during cell culture. Addition of PEI to the cell culture as a fermentation enhancer can result in reducing the viscosity of the cell culture, and/or increasing the extracellular concentration of the recombinant protein, and/or reducing the duration of cell culture to the point of harvest or protein recovery.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 6, 2023
    Assignee: Glaxo Group Limited
    Inventors: Gary Brian Finka, Michael Hoare, Mark Uden, Ioannis Voulgaris
  • Patent number: 11661442
    Abstract: Vesicles that incorporate reporting constructs for characterizing Botulinum neurotoxin protease activity and suitable for use in an assay are provided. The reporting constructs are a pair of recombinant hybrid proteins that act in concert. The reporting constructs are a pair of recombinant hybrid proteins that act in concert, and that include a Botulinum neurotoxin protease recognition and cleavage sequence positioned to release a fluorophore upon cleavage.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: May 30, 2023
    Assignee: BioMadison, Inc.
    Inventors: Ward C Tucker, Francis Mark Dunning
  • Patent number: 11661613
    Abstract: Methods and materials for the production of hydroxy fatty acid anions, including 2-hydroxyisobutyric acid (2-HIBA), and/or derivatives thereof and compounds related thereto are provided. Also provided are products produced in accordance with these methods and materials.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 30, 2023
    Assignee: INV NYLON CHEMICALS AMERICAS, LLC
    Inventors: Jonathan Paul Combe, Alexander Brett Foster, Arghya Barman
  • Patent number: 11648272
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: May 16, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
  • Patent number: 11630109
    Abstract: The present invention provides compositions comprising chimeric polypeptides that bind to free ubiquitin proteins or free ubiquitin-like proteins with high affinity, as well as chimeric polypeptides that bind to both free and conjugated ubiquitin proteins or free and conjugated ubiquitin-like proteins, and methods of using the chimeric polypeptides to determine the amount of free or total ubiquitin or free or total ubiquitin-like proteins in various types of samples.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: April 18, 2023
    Assignee: Colorado State University Research Foundation
    Inventors: Robert E. Cohen, Yun-Seok Choi
  • Patent number: 11618893
    Abstract: The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: April 4, 2023
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Efrat Eliyahu, Adam Vincek, Anthony Fargnoli, Michael Katz
  • Patent number: 11603522
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: March 14, 2023
    Assignees: NOVOZYMES A/S, NOVOZYMES NORTH AMERICA, INC.
    Inventors: Carsten Andersen, Randall Deinhammer, Thomas Agersten Poulsen, Miguel Duarte Toscano, Peter Kamp Hansen, Henrik Friis-Madsen, Anders Viksoe-Nielsen, Signe Eskildsen Larsen, Lars L. H. Christensen
  • Patent number: 11597959
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • Patent number: 11597917
    Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: March 7, 2023
    Assignees: The Medical College of Wisconsin, Inc., University Health Network, Washington University in St. Louis
    Inventors: Jeffrey A. Medin, John F. Dipersio, Murtaza S. Nagree
  • Patent number: 11578342
    Abstract: The disclosure discloses recombinant Bacillus subtilis for synthesizing guanosine diphosphate fucose and a construction method and application thereof. The recombinant Bacillus subtilis is obtained by intensively expressing guanylate kinase and nucleotide diphosphokinase genes and expressing exogenous fucokinase and phosphate guanylyltransferase genes in a genome of Bacillus subtilis 168. According to the disclosure, a bacterial strain for synthesizing the guanosine diphosphate fucose is obtained by reconstructing the Bacillus subtilis 168, with a volume of intracellular accumulation up to 196.15 g/L. According to the disclosure, by intensively expressing the guanylate kinase and nucleotide diphosphokinase genes, and enhancing the supply of intracellular GDP-L-fucose composition cofactors, the synthesis of the guanosine diphosphate fucose is promoted. The construction method for the recombinant Bacillus subtilis of the disclosure is simple and convenient to use, thus having good application prospects.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: February 14, 2023
    Assignees: BRIGHT DAIRY & FOOD CO., LTD., Jiangnan University
    Inventors: Long Liu, Jian Chen, Guocheng Du, Jieying Deng, Chunmei Chen, Xueqin Lv, Jianghua Li
  • Patent number: 11572552
    Abstract: Reported herein is a sortase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 11 and that comprises the mutations D101S and K137S.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 7, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Mara Boenitz-Dulat, Martin Schatte